Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Naomi Bradbury, Jonathan Nguyen-Van-Tam, Wei Shen Lim

ABSTRACT

BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza. METHODS: Senior clinicians (n = 50) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs. RESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial. CONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo. More... »

PAGES

311

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x

DOI

http://dx.doi.org/10.1186/s12913-018-3122-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103738626

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29716584


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Attitude of Health Personnel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoside Hydrolase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Influenza, Human", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Staff, Hospital", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuraminidase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oseltamivir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Personnel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Zanamivir", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Warwick", 
          "id": "https://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Zeeman Institute: Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, CV4 7AL, Coventry, UK", 
            "School of Life Sciences, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bradbury", 
        "givenName": "Naomi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Faculty of Medicine & Health Sciences, University of Nottingham. Clinical Sciences Building, Nottingham City Hospital, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nguyen-Van-Tam", 
        "givenName": "Jonathan", 
        "id": "sg:person.01317574115.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317574115.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lim", 
        "givenName": "Wei Shen", 
        "id": "sg:person.012720025352.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012720025352.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/bmj.g2545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004439783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)61734-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007587958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.04623-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014888384"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)62449-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018993023"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/15265161.2015.1010993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025900421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0001296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030246057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(14)70041-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030941184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jinf.2013.11.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031506364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198707163170304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043033182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3201/eid2206.151037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049764978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(15)70106-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052987598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0079360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053423666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0079360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053423666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2011-200081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053544632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2011-200081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053544632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/medethics-2016-103474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062819666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/medethics-2016-103474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062819666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2807/1560-7917.es2015.20.11.21065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070926445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta19160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2807/1560-7917.es.2017.22.14.30506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084954433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.j2841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085998696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.j2841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085998696"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza.\nMETHODS: Senior clinicians (n\u00a0=\u200950) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs.\nRESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial.\nCONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12913-018-3122-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1327417", 
        "issn": [
          "1472-6963"
        ], 
        "name": "BMC Health Services Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Clinicians\u2019 attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza", 
    "pagination": "311", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2a3c22a2da426e8cd5ed219da38866756423496f8b9bda848e218d5d54a42410"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29716584"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101088677"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12913-018-3122-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103738626"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12913-018-3122-x", 
      "https://app.dimensions.ai/details/publication/pub.1103738626"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89801_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12913-018-3122-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      21 PREDICATES      62 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12913-018-3122-x schema:about N00a21f6c491d4fb89a081b5c899cf92a
2 N1db580674a3e43e1bffd06f8b6b76f6c
3 N27a4da61996b48a4a6cd17df4a04823e
4 N299f1394ab6e42169740ad05c9f39302
5 N3a814ca3deb8493caa5e0efd76d4e58c
6 N44126cf1f7f14990a990d0f874e960c8
7 N4b64cf7cc61f452fbab659022f904e9c
8 N5d693ddad496410192f1d8d119a9797c
9 N7eb99432b4cf4b06ab1aa2377282752e
10 N8944a2c8f12e42d1bbd4cd7c8fe27eb1
11 N8d157fdc40a5470788447a80c1310078
12 N8f4fc3ea74bc4a7a91eed5ffc3a15634
13 Nca2bd946804148dc98627dec93950c5c
14 Ne5d9d64c9aca4c5a9f2a323a2cac41b1
15 Nefbd7e2e813a4c9dbae97909b4deca97
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Ne0772be289ea4b72887dfdbfc59c5103
19 schema:citation https://doi.org/10.1016/j.jinf.2013.11.013
20 https://doi.org/10.1016/s0140-6736(14)61734-7
21 https://doi.org/10.1016/s0140-6736(14)62449-1
22 https://doi.org/10.1016/s1473-3099(15)70106-4
23 https://doi.org/10.1016/s2213-2600(14)70041-4
24 https://doi.org/10.1056/nejm198707163170304
25 https://doi.org/10.1080/15265161.2015.1010993
26 https://doi.org/10.1128/aac.04623-14
27 https://doi.org/10.1136/bmj.g2545
28 https://doi.org/10.1136/bmj.j2841
29 https://doi.org/10.1136/medethics-2016-103474
30 https://doi.org/10.1136/thoraxjnl-2011-200081
31 https://doi.org/10.1371/journal.pone.0001296
32 https://doi.org/10.1371/journal.pone.0079360
33 https://doi.org/10.2807/1560-7917.es.2017.22.14.30506
34 https://doi.org/10.2807/1560-7917.es2015.20.11.21065
35 https://doi.org/10.3201/eid2206.151037
36 https://doi.org/10.3310/hta19160
37 schema:datePublished 2018-12
38 schema:datePublishedReg 2018-12-01
39 schema:description BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza. METHODS: Senior clinicians (n = 50) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs. RESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial. CONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N040e697f6da54a53b5cb16061a1a2387
44 N51b76ec6361d47b697f0472733e74ccf
45 sg:journal.1327417
46 schema:name Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza
47 schema:pagination 311
48 schema:productId N348416256db94831b2189a996f77d515
49 N45a3b0d086604d78b7fc1302dcdf6748
50 N9643af326c5f4597a0452768006f608a
51 Ndec016710c794df0a54d49394591c1f9
52 Neb472abbcf8440c38f63679622ade8fd
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103738626
54 https://doi.org/10.1186/s12913-018-3122-x
55 schema:sdDatePublished 2019-04-11T09:55
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Nf85ca8a50a594da0b6598022d573e3a8
58 schema:url https://link.springer.com/10.1186%2Fs12913-018-3122-x
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N00a21f6c491d4fb89a081b5c899cf92a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Randomized Controlled Trials as Topic
64 rdf:type schema:DefinedTerm
65 N040e697f6da54a53b5cb16061a1a2387 schema:volumeNumber 18
66 rdf:type schema:PublicationVolume
67 N1db580674a3e43e1bffd06f8b6b76f6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Adult
69 rdf:type schema:DefinedTerm
70 N27a4da61996b48a4a6cd17df4a04823e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Antiviral Agents
72 rdf:type schema:DefinedTerm
73 N299f1394ab6e42169740ad05c9f39302 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Influenza, Human
75 rdf:type schema:DefinedTerm
76 N348416256db94831b2189a996f77d515 schema:name pubmed_id
77 schema:value 29716584
78 rdf:type schema:PropertyValue
79 N3a814ca3deb8493caa5e0efd76d4e58c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Zanamivir
81 rdf:type schema:DefinedTerm
82 N44126cf1f7f14990a990d0f874e960c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Oseltamivir
84 rdf:type schema:DefinedTerm
85 N45a3b0d086604d78b7fc1302dcdf6748 schema:name dimensions_id
86 schema:value pub.1103738626
87 rdf:type schema:PropertyValue
88 N4b64cf7cc61f452fbab659022f904e9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 N4d6933013de140b196045184adc06c43 rdf:first sg:person.012720025352.64
92 rdf:rest rdf:nil
93 N51b76ec6361d47b697f0472733e74ccf schema:issueNumber 1
94 rdf:type schema:PublicationIssue
95 N5d693ddad496410192f1d8d119a9797c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Attitude of Health Personnel
97 rdf:type schema:DefinedTerm
98 N7eb99432b4cf4b06ab1aa2377282752e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Research Personnel
100 rdf:type schema:DefinedTerm
101 N8944a2c8f12e42d1bbd4cd7c8fe27eb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Glycoside Hydrolase Inhibitors
103 rdf:type schema:DefinedTerm
104 N8b9bc12d18d9442e93eabdfea397ba2c schema:affiliation https://www.grid.ac/institutes/grid.7372.1
105 schema:familyName Bradbury
106 schema:givenName Naomi
107 rdf:type schema:Person
108 N8d157fdc40a5470788447a80c1310078 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name United Kingdom
110 rdf:type schema:DefinedTerm
111 N8f4fc3ea74bc4a7a91eed5ffc3a15634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Neuraminidase
113 rdf:type schema:DefinedTerm
114 N9643af326c5f4597a0452768006f608a schema:name nlm_unique_id
115 schema:value 101088677
116 rdf:type schema:PropertyValue
117 Nca2bd946804148dc98627dec93950c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hospitalization
119 rdf:type schema:DefinedTerm
120 Ndec016710c794df0a54d49394591c1f9 schema:name doi
121 schema:value 10.1186/s12913-018-3122-x
122 rdf:type schema:PropertyValue
123 Ndfab61b67f21432590fe2f4089499b09 rdf:first sg:person.01317574115.29
124 rdf:rest N4d6933013de140b196045184adc06c43
125 Ne0772be289ea4b72887dfdbfc59c5103 rdf:first N8b9bc12d18d9442e93eabdfea397ba2c
126 rdf:rest Ndfab61b67f21432590fe2f4089499b09
127 Ne5d9d64c9aca4c5a9f2a323a2cac41b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Surveys and Questionnaires
129 rdf:type schema:DefinedTerm
130 Neb472abbcf8440c38f63679622ade8fd schema:name readcube_id
131 schema:value 2a3c22a2da426e8cd5ed219da38866756423496f8b9bda848e218d5d54a42410
132 rdf:type schema:PropertyValue
133 Nefbd7e2e813a4c9dbae97909b4deca97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Medical Staff, Hospital
135 rdf:type schema:DefinedTerm
136 Nf85ca8a50a594da0b6598022d573e3a8 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
142 schema:name Clinical Sciences
143 rdf:type schema:DefinedTerm
144 sg:journal.1327417 schema:issn 1472-6963
145 schema:name BMC Health Services Research
146 rdf:type schema:Periodical
147 sg:person.012720025352.64 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
148 schema:familyName Lim
149 schema:givenName Wei Shen
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012720025352.64
151 rdf:type schema:Person
152 sg:person.01317574115.29 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
153 schema:familyName Nguyen-Van-Tam
154 schema:givenName Jonathan
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317574115.29
156 rdf:type schema:Person
157 https://doi.org/10.1016/j.jinf.2013.11.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031506364
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/s0140-6736(14)61734-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007587958
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/s0140-6736(14)62449-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018993023
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1016/s1473-3099(15)70106-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052987598
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1016/s2213-2600(14)70041-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030941184
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1056/nejm198707163170304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043033182
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1080/15265161.2015.1010993 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025900421
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1128/aac.04623-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014888384
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1136/bmj.g2545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004439783
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1136/bmj.j2841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085998696
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1136/medethics-2016-103474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062819666
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1136/thoraxjnl-2011-200081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053544632
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1371/journal.pone.0001296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030246057
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1371/journal.pone.0079360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053423666
184 rdf:type schema:CreativeWork
185 https://doi.org/10.2807/1560-7917.es.2017.22.14.30506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084954433
186 rdf:type schema:CreativeWork
187 https://doi.org/10.2807/1560-7917.es2015.20.11.21065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070926445
188 rdf:type schema:CreativeWork
189 https://doi.org/10.3201/eid2206.151037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049764978
190 rdf:type schema:CreativeWork
191 https://doi.org/10.3310/hta19160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139472
192 rdf:type schema:CreativeWork
193 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
194 schema:name Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, NG5 1PB, Nottingham, UK
195 Faculty of Medicine & Health Sciences, University of Nottingham. Clinical Sciences Building, Nottingham City Hospital, NG5 1PB, Nottingham, UK
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.7372.1 schema:alternateName University of Warwick
198 schema:name School of Life Sciences, University of Warwick, CV4 7AL, Coventry, UK
199 Zeeman Institute: Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, CV4 7AL, Coventry, UK
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...